Call the HEPLISAV-B Pregnancy Registry toll-free number 1-844-443-7734
OR email: heplisavbpregnancyregistry@ppdi.com
INDICATION AND IMPORTANT SAFETY INFORMATION

What is required to be eligible to participate?

  • The patient must be at least 18 years of age.
  • The patient must currently be pregnant, or have already delivered, and the infant has been diagnosed with a birth defect.
  • The patient must have received a dose of the hepatitis B vaccine HEPLISAV-B within 28 days prior to conception or during their pregnancy. Patients will not be vaccinated as part of the study.
  • The patient must agree to provide personal and healthcare provider contact information and consent for release of medical information for them and their infant. Once enrolled we will collect all necessary information from you and the infant’s respective healthcare providers.

How can I help my patients join the HEPLISAV-B Pregnancy Registry?

Doctors or healthcare providers should encourage their patients to enroll in the pregnancy registry. To assist your patients in joining, simply provide them with the following:

Once a patient is consented….

  • We will request that you provide information that is routinely collected in the course of usual care.
  • Maternal healthcare providers will be contacted at registration, at the end of the 2nd trimester and at pregnancy outcome.
  • Pediatric healthcare providers will be contacted when the infant is 12 months of age.

How can I learn about HEPLISAV-B and the Registry data collected to date?

Ways to enroll in the HEPLISAV-B® Pregnancy Registry

Call Heplisav-B Pregnancy Registry
Call our toll-free number
Download Participant Consent form
Download
(Fill it out and send it to us via email or fax (1-877-202-3940))

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

References: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Emeryville, CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.

CLICK HERE FOR FULL PRESCRIBING INFORMATION
Heplisav-B